Amicus Therapeutics Company Insiders

FOLD Stock  USD 14.29  0.02  0.14%   
Amicus Therapeutics employs about 499 people. The company is managed by 19 executives with a total tenure of roughly 51 years, averaging almost 2.0 years of service per executive, having 26.26 employees per reported executive. Evaluation of Amicus Therapeutics' management performance can provide insight into the firm performance.
John Crowley  Chairman
Executive Chairman
Jill Weimer  President
Senior Vice President of Discovery Research and Gene Therapy Science
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Amicus Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of 0.0261 % which means that it generated a profit of $0.0261 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0687) %, meaning that it created substantial loss on money invested by shareholders. Amicus Therapeutics' management efficiency ratios could be used to measure how well Amicus Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
The majority of Amicus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amicus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amicus Therapeutics. Please pay attention to any change in the institutional holdings of Amicus Therapeutics as this could imply that something significant has changed or is about to change at the company.
Some institutional investors establish a significant position in stocks such as Amicus Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Amicus Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Amicus Therapeutics Workforce Comparison

Amicus Therapeutics is rated # 3 in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 5,527. Amicus Therapeutics holds roughly 499 in number of employees claiming about 9% of equities under Health Care industry.
The company has Profit Margin (PM) of (0.02) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.2 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.2.

Amicus Therapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amicus Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amicus Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Amicus Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Amicus Therapeutics Notable Stakeholders

An Amicus Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Amicus Therapeutics often face trade-offs trying to please all of them. Amicus Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Amicus Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Bradley MBAPresident CEOProfile
John CrowleyExecutive ChairmanProfile
Jill WeimerSenior Vice President of Discovery Research and Gene Therapy ScienceProfile
Jeffrey CastelliVice President - Program and Portfolio ManagementProfile
Anthony SilenoSenior SciencesProfile
David ClarkChief OfficerProfile
Patrik EsqGlobal OfficerProfile
Michael KeavanySenior BusinessProfile
Sbastien MartelChief OfficerProfile
Patrik FlorencioGlobal VPProfile
Simon HarfordChief OfficerProfile
Ellen RosenbergGeneral Counsel and Corporate SecretaryProfile
Ellen JDChief SecretaryProfile
Samantha ProutPrincipal Accounting Officer, ControllerProfile
Simon JordanChief DiseasesProfile
Andrew FaughnanDirector RelationsProfile
Diana MooreHead CommunicationsProfile
Brendan McEvoyExecutive CommunicationsProfile
Jayne GershkowitzChief AdvocateProfile
String symbol = request.getParameter("s");

About Amicus Therapeutics Management Performance

The success or failure of an entity such as Amicus Therapeutics often depends on how effective the management is. Amicus Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Amicus management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Amicus management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Amicus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 496 people.
Please note, the presentation of Amicus Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Amicus Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Amicus Therapeutics' management manipulating its earnings.

Amicus Therapeutics Workforce Analysis

Traditionally, organizations such as Amicus Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Amicus Therapeutics within its industry.

Amicus Therapeutics Manpower Efficiency

Return on Amicus Therapeutics Manpower

Revenue Per Employee1.1M
Revenue Per Executive27.8M
Net Loss Per Employee112.4K
Net Loss Per Executive3M
Working Capital Per Employee713.5K
Working Capital Per Executive18.7M

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios